InnoModels PBMC Pre-screening: Ensuring Immune System Reconstruction Success Rate and Dosing Window
Our InnoModels PBMCs undergo internal screening to ensure that PBMCs, pre-screened in vivo, are suitable for experiments, thereby ensuring a successful rate and a dosing window of 3 weeks.
Our InnoModels PBMC pre-experiment screening criteria include:
● After 14 days of inoculation, the percentage of peripheral blood hCD45+ cells must exceed 10%.
● The appearance of Graft-Versus-Host Disease (GVHD) should be equal to or exceed 5 weeks, with weight loss not exceeding 10%.
● Comprehensive analysis of PBMCs.
PBMC-Tumor Pre-experiment Platform
Peripheral Blood Mononuclear Cells (PBMCs) are derived from healthy donors, and the reconstruction ability varies among different donors. Furthermore, their interactions with tumor cells and immune responses to immunotherapeutic drugs are all unique. Moreover, a significant advantage of the PBMC model is its applicability to various types of tumor cells, providing multiple targeting options for testing the effectiveness of immunotherapies. However, due to variations in the antagonistic interactions between different tumor cells and PBMCs, historical data has limited significance when transitioning to new donors. Therefore, pre-experiments are crucial for determining compatible PBMC donors for candidate tumor cells.
● Stable iHuPBMC reconstruction and compatibility. Over 90% of human tumor cells can be selected for reconstruction from three donors.
● Providing in vivo and in vitro pre-screening platforms to meet diverse customer needs.
● Large-scale PBMC donor backup, ensuring stable donor use throughout consecutive projects.
● Simultaneous screening based on drug efficacy.
Through pre-experiments, InnoModels ensures the optimal compatibility of PBMCs with tumor cells, thereby enhancing the reliability and effectiveness of immune tumor research and drug testing.

InnoModels‘s PBMC efficacy study QC checkpoints